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Background: Cytotoxic chemotherapy brings routine cures to only a small select group of metastatic malignancies
comprising gestational trophoblast tumours, germ cell tumours, acute leukemia, Hodgkin’s disease, high grade
lymphomas and some of the rare childhood malignancies.
We have previously postulated that the extreme sensitivity to chemotherapy for these malignancies is linked to
the on-going high levels of apoptotic sensitivity that is naturally linked with the unique genetic events of nuclear
fusion, meiosis, VDJ recombination, somatic hypermutation, and gastrulation that have occurred within the cells of
origin of these malignancies.
In this review we will examine the cancer stem cell/cancer cell relationship of each of the chemotherapy curable
malignancies and how this relationship impacts on the resultant biology and pro-apoptotic sensitivity of the varying
cancer cell types.
Discussion: In contrast to the common epithelial cancers, in each of the chemotherapy curable malignancies there are
no conventional hierarchical cancer stem cells. However cells with cancer stem like qualities can arise stochastically
from within the general tumour cell population. These stochastic stem cells acquire a degree of resistance to DNA
damaging agents but also retain much of the key characteristics of the cancer cells from which they develop.
We would argue that the balance between the acquired resistance of the stochastic cancer stem cell and the
inherent chemotherapy sensitivity of parent tumour cell determines the overall chemotherapy curability of each
diagnosis.
Summary: The cancer stem cells in the chemotherapy curable malignancies appear to have two key biological
differences from those of the more common chemotherapy incurable malignancies. The first difference is that
the conventional hierarchical pattern of cancer stem cells is absent in each of the chemotherapy curable
malignancies.
The other key difference, we suggest, is that the stochastic stem cells in the chemotherapy curable malignancies
take on a significant aspect of the biological characteristics of their parent cancer cells. This action includes for
the chemotherapy curable malignancies the heightened pro-apoptotic sensitivity linked to their respective
associated unique genetic events.
For the chemotherapy curable malignancies the combination of the relationship of their cancer stem cells combined
with the extreme inherent sensitivity to induction of apoptosis from DNA damaging agents plays a key role in
determining their overall curability with chemotherapy.
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Background
Despite the introduction of a significant number of new
cancer therapeutics that target specific molecular path-
ways within malignant cells, the use of DNA damaging
cytotoxic chemotherapy currently remains the mainstay
in the management of most malignancies [1].
In the majority of metastatic malignancies, DNA dam-
aging cytotoxic chemotherapy can reduce the disease
bulk, improve symptoms and extend life [2]. However,
despite these often significant benefits from treatment,
curative treatment with chemotherapy is not a realistic
outcome for patients with the common metastatic malig-
nancies. In contrast in a select group of relatively rare ma-
lignancies, curative treatment with chemotherapy drugs is
the expectation even for the patients with widely dissemi-
nated and high tumor burden disease [3].
Beginning in the 1950s and fully established by the
1980s there has been the development of routine cura-
tive chemotherapy treatment for most patients with
acute leukemia, high grade non-Hodgkin’s lymphoma
(NHL), Hodgkin’s disease, testicular and ovarian germ
cell tumors, the gestational trophoblast tumors and for
many cases of the rare childhood malignancies [2, 4]. In
current practice the cure rates for a number of these
diagnoses is in excess of 90%, with the first line cytotoxic
drug treatment of each malignancy comprised entirely of
drugs developed by the early 1980s. Whilst there is sig-
nificant short term toxicity from chemotherapy, gener-
ally treatment is relatively well tolerated and patients are
routinely cured. After treatment patients return to nor-
mal health and appear to have no significant long term
toxicity to any cell types or to their tissue specific
healthy somatic stem cells [5].
There is clearly a significant clinical and biological div-
ide between these rarer malignancies that can be routinely
cured with cytotoxic chemotherapy and the majority of
the more common cancers that are incurable in the meta-
static setting and only relatively rarely cured even in the
adjuvant setting. The biological explanation for this diver-
gence presents a significant challenge to both understating
of the cellular processes involved and to the development
of more effective approaches to care [6, 7].
With such a routine but dramatic and reproducible div-
ide in chemotherapy sensitivity and treatment outcomes
between these differing tumor cell types, the conventional
explanations that ascribe chemotherapy resistance to the
two main continuous variable parameters of the rate of
tumour cell growth and the development of genetic muta-
tions that lead to resistance are perhaps worthy of an up-
dated review.
Historically the concept of the inherent chemotherapy
sensitivity of tumour cells and the concept of ‘log kill’
originated in early models that used murine leukemia as
the model [8, 9]. As we will review later, acute leukemia
may well be deeply unrepresentative of the biology of
the majority of tumor cell types. As a result the inter-
pretation of experimental data from this cell type should
be handled with caution with regard to the unique
biological properties of these early B cell malignancies
compared to that of the more common epithelial
malignancies.
We have recently suggested an alternate biological ex-
planation for the extreme chemotherapy sensitivity of
the chemotherapy curable malignancies. The theory cen-
tres on the close association between the cells of the
chemotherapy curable malignancies and the occurrence
of their unique genetic events of nuclear fusion, mei-
osis, variable-diversity-joining (VDJ) recombination,
and somatic hypermutation (SHM) each of which has
naturally upregulated apoptotic pathways as shown in
Table 1 [3, 4]. In this updated review we will examine
the relationship between cancer stem cell biology, the
developmental pathways of the chemotherapy curable
malignancies and the potential impact these have on
the natural apoptotic sensitivity of the cancer stem cells
in the differing diagnoses.
Cancer stem cells; Hierarchical and stochastic
The existence and important role of cancer stem cells
appears to support many of the clinical observations on
malignant cells and their responses to treatment. Whilst
their existence was originally suggested in the 19th cen-
tury [10], cancer stem cells were first identified in the
1990s, in acute myeloid leukemia (AML) [11, 12]. Fur-
ther studies have now observed cancer stem cells in a
wide range of malignancies including glioblastoma,
breast, endometrial, pancreatic, prostate, lung, colon
cancers and a range of other tumor types [13–17]. Over-
all cancer stem cells are characterised as having distinct
key properties including: self renewal, the ability to dif-
ferentiate, active anti-apoptotic pathways, the expression
of CD44, aldehyde dehydrogenase, CD133 and other
markers also expressed by normal tissue specific somatic
stem cells [18].
The importance of tissue specific somatic stem cells
on cancer biology and therapeutics is twofold. Firstly,
the existence of tissue specific stem cells allows for cells
to be sufficiently long lived to be able to accumulate the
number of mutations required to develop the malignant
phenotype [18]. The second characteristic of tissue spe-
cific stem cells is that they have an intrinsically biologic-
ally damage resistant phenotype that allows the tissue
specific stem cells to be resistant to natural adverse chal-
lenges. This phenotype is that result of two processes,
the first the presence of multiple systems including
ATP-binding cassette (ABC) transporter proteins, that
help protect the stem cell from any genotoxic agents
[19, 20] and secondly the low level of apoptotic response
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to any DNA damage results in the resistance to chemo-
therapy treatment that may kill cancer cells and more
mature normal healthy cells.
The resistance to chemotherapy of the normal tissue
specific somatic stem cells appears to be routinely
shared by the stem cells that have undergone malignant
transformation and have become cancer stem cells [21].
It is believed that the natural resistance of the cancer
stem cells to chemotherapy treatment may contribute to
the underlying chemotherapy resistance of the common
malignancies [14, 22, 23].
The main cancer stem cell model relates to cancer
stem cells that form a hierarchy in giving rise to the
tumour cells, following the linear progression from som-
atic stem cell to cancer stem cell and then to cancer cell.
However there is also evidence that cells with some
similar properties of stemness can arise from within the
tumour cell pool in the stochastic cancer stem cell
model. However these cancer stem cells having a differ-
ent aetiology to hierarchical stem cells and the potential
to have different biological characteristics. These two ap-
proaches to cancer stem cells are not mutually exclusive
with stochastic cancer stem cells being reported in colon
cancer that is also supported by a hierarchical cancer
stem system [24].
The malignant phenotype and inhibition of
developmental progression
By definition the development of the malignant pheno-
type dramatically affects the biology of the cell with a
major impact on the inhibition of normal patterns of
cellular differentiation, senescence, ageing and pro-
grammed cell death [25]. The result of these processes is
to lead to the accumulation of excess cells, a lack of con-
trol of numbers, abnormal development patterns and
the inhibition of apoptosis that is normal part of the nat-
ural history of healthy cells.
The most dramatic impact of the onset of the malig-
nant phenotype on altering cellular development can be
seen in B and T cell malignancies which arise at a num-
ber of differing points along the normal but complex
linear lymphocyte development pathways. In these ma-
lignancies, the malignant cells appear to become devel-
opmentally frozen with no further progression in the
normal inear development of these cells from the time
of the onset of the malignant phenotype [26]. As a result
B cell malignancies that arise at differing points in B cell
development can give rise to a wide spectrum of malig-
nancies ranging from acute lymphocyctic leukemia
(ALL), through chronic lymphocytic leukemia (CLL),
mantle cell lymphoma, diffuse large B cell lymphoma
(DLBCL), Hodgkin’s disease, follicular lymphoma, and
on to multiple myeloma. The actual diagnosis and treat-
ment related prognosis being dependant on the point in
B cell development when the malignant phenotype is
established and further cellular development halted [27].
More recently we have postulated how the impact of
the onset of malignancy on freezing the cells normal
developmental progression may leave malignant cells
developing at certain normally transient but key devel-
opmental points with fixed heightened physiological
pro-apoptotic potential [3]. For each of the chemotherapy
Table 1 Cancer stem cell structure, associated unique genetic events and chemotherapy curability
Metastatic malignancy Cancer stem cell model Associated unique genetic event Chemotherapy curability
Common epithelial cancers Hierarchical None -
Gestational trophoblast tumours Non-hierarchical Nuclear fusion +++
Germ cell tumours Non-hierarchical Meiosis +++
Childhood malignancies Non-hierarchical Gastrulation +
B and T cell malignancies
Acute undifferentiated leukemia Hierarchical None -
Acute lymphocytic leukemia Non-hierarchical VDJ +++
ALK + ve T Cell lymphoma Non-hierarchical VDJ ++
Mantle cell lymphoma Non-hierarchical None -
Diffuse large B Cell lymphoma Non-hierarchical SHM ++
Burkitt’s lymphoma Non-hierarchical SHM ++
Hodgkin lymphoma Non-hierarchical SHM ++
CLL Non-hierarchical None -
Myeloma Non-hierarchical None -
Mature T cell malignancies Non-hierarchical None -
The relationship of the cancer stem cell model, of being either hierarchical as in the common epithelial cancers or non-hierarchical without somatic stem derived
cancer stem cells, the associated unique genetic events and the associated degree of chemotherapy curability are shown. For simplicity chemotherapy curability is
shown on a zero to 3 star range
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curable malignancies there appears to be a close associ-
ation with a unique physiological genetic event and their
naturally associated relevant pro-apoptotic pathways.
These events are nuclear fusion for gestational trophoblast
tumors, meiosis for germ cell tumours, VDJ recombin-
ation for ALL and anaplastic lymphoma kinase (ALK) + ve
T cell NHL, somatic hypermutation (SHM) for DLBCL,
Hodgkin’s disease and Burkitt’s lymphoma and gastrula-
tion for the rare childhood malignancies. Based on the
assumption that the onset of malignancy occurs closely
related to these events, we have postulated the persist-
ence of the naturally upregulated pro-apoptotic ma-
chinery associated with these events remaining active
and that this may be a likely major contributor to the
ease of cure of these malignancies with chemotherapy
treatment [4].
Cancer cell of origin, ABC transporter proteins and
chemotherapy sensitivity
Alongside the major contribution made to chemother-
apy responses of the chemotherapy curable malignancies
by the apoptotic sensitivity associated with their associ-
ated unique genetic developments, the ABC transport
proteins also plays an important role in determining
chemotherapy responses [28, 29].
A number of studies have indicated that the expres-
sion of this family of molecules is associated with a re-
duction in the efficacy of chemotherapy as a result of
the increased efflux of drugs from cancer cells [30, 31].
However despite this important role, clinical develop-
ments to reverse this impact have not to date been of
significant success [32–35].
The relationship between stem cells, the cancer cell of
origin, the expression of the ABC system and the re-
sponse to chemotherapy treatment in the chemotherapy
curable malignancies helps to define the unique biology
of these cells.
The ABC protein system is widely expressed in con-
ventional tissue specific stem cells, where it plays a key
role in protecting these cells from genotoxic stress [36].
Similarly in epithelial cancer stem cells, which are de-
rived from tissue specific stem cells, ABC proteins are
documented to be persistently expressed [37–39]. In the
majority of solid tumours further increases in ABC pro-
tein expression levels have been associated with declin-
ing sensitivity to chemotherapy [40, 41].
However, as previously discussed, in the chemother-
apy curable malignancies, there are no standard hier-
archical cancer stem cells derived from the tissue
specific stem cells and each of these malignancies arises
from a transient developmental cell. It is apparent that
these transient developmental cells have very differing
patterns of ABC protein expression compared to tissue
specific stem cells and this status appears to impact
significantly on the expression of ABC proteins in ma-
lignancies derived from them.
In normal trophoblast cells, assessment of the expres-
sion and functional activity of ABC transporter genes in
murine embryos indicate that activity of these efflux sys-
tems is not present immediately post nuclear fusion but
only becomes active by day 6 [42]. Pathological studies
demonstrate that in molar pregnancies there is only
focal and much lower levels of the multi-drug resistance
transporter ABCB5 expression than is seem in normal
first trimester placentas [43]. This observation suggests
that the failure of molar pregnancies to successfully
undergo nuclear fusion and subsequent cellular differen-
tiation is associated with an inhibition of the cellular de-
velopment that would normally include the normal
increase in expression of ABC proteins.
There is less data on the expression of the ABC family
proteins in choriocarcinoma and placental site tropho-
blast tumours, however the limited data indicates that
the majority of cases of choriocarcinoma or PSTT do
not express ABCB5 [43].
B and T cell malignancies arise from differing transient
cell types occurring along the lymphocyte development
pathways [26]. The level of ABC protein expression at
these points can vary significantly and this can impact
on the lasting phenotype and chemotherapy sensitivity
of the resultant malignancies. In normal B cells, studies
have indicated high levels of functional activity for the
efflux pump systems in HSCs but that these levels de-
cline sharply in cells as they become committed as 34
+/38+, 34+/33+, or 34+/10+ progenitor cells [44]. A
wider review of ABC protein expression indicates that
their activity varies across B cell development from a
peak as HSC then falling during B cell development and
then rising again in plasma cells [45].
Data suggests that this variation in ABC protein activ-
ity during normal B cell development is reflected in the
various malignancies arising along the course of lympho-
cyte development. A number of studies have indicated
that there the expression of ABC family members is sig-
nificantly lower in both B cell and T cell ALL than in
HSCs [46]. This reduction in the ABC activity marks
that the ALL cells have, on entering VDJ rearrangement,
moved away from the phenotype of the chemotherapy
resistant HSC and the low level of ABC protein expres-
sion may in part be linked to the sensitivity of ALL to
chemotherapy.
In Hodgkin’s lymphoma which is believed to arise
from germinal centre B cells, the majority of cases do
not express ABC proteins. Of note a more recent study
has indicated that the approximately 30% of Hodgkin’s
cases that do express the ABCC1 protein have a ten-
dency to a worse prognosis [47]. Similarly in DLBCL ex-
pression of the ABC system is highly variable between
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cases and the outcome is worse in patients with higher
levels of expression [48].
In contrast in CLL, levels of ABC proteins are higher
than in DLBCL [49] and myeloma which develops from
cells in the final stage of B cell development expresses
ABC proteins at higher levels which can rise further on
exposure to chemotherapy [50].
In testicular cancer characteristically the majority of
ABC proteins are expressed at only very low levels, with
significant levels of expression only seen in tumours that
have demonstrated chemotherapy resistance [51]. The
presumed cell of origin of testicular cancer is intrae-
pithelial germ cell neoplasia which arises from a defect
in gonocyte development. There is limited information
on the expression of ABC proteins in these cells, but
these cancer precursor cells are, unlike hierarchical can-
cer stem cells, very sensitive to chemotherapy [52] and it
is likely that low or absent ABC expression will occur in
these unique cells.
Reviewing the chemotherapy curable malignancies as
a group it is apparent that they have this additional
shared characteristic of generally low levels of ABC
protein expression. This finding is intrinsically linked
to particular cells of origin of these malignancies being
transient developmental cells. Each of these develop-
mental cells themselves have low ABC expression, ra-
ther than the high levels that are seen in hierarchical
cancer stem cells. The relative role that these low
levels of ABC expression plays compared to the impact
of the unregulated apoptotic pathways associated with
the unique genetic events occurring in these cells is an
area to debate and hopefully one with interesting data
to come.
Discussion
Cancer stem cells and chemotherapy curability
In the common epithelial malignancies the conventional
structure of the cancer stem cell is the hierarchical system
as shown in Fig. 1. In this system the cancer stem cells
arise from somatic stem cells and give rise to their progeny
of malignant cells which go on to form the bulk of the
tumour. In response to chemotherapy treatment the pro-
geny cancer cells in some diagnoses can respond dramatic-
ally to treatment, as seen in small cell lung cancer or
epithelial ovarian cancer. However the cancer stem cells do
not share the sensitivity to chemotherapy of their progeny
tumour cells, but rather have the characteristic chemother-
apy resistance of the tissue specific somatic stem cells. As a
result the cancer stem cells survive the chemotherapy
treatment and can then serve to repopulate the tumour
and the cancer is hence destined to clinically relapse [21].
In contrast in the chemotherapy curable malignancies
the role and relationship of potential cancer stem cells
appears to be significantly different in both the hierarchy
of the cancer stem cell/cancer cell relationship and also
of crucial importance in the characteristics of the cancer
stem cell with regards to sensitivity to chemotherapy.
Cancer stem cells in the chemotherapy curable malig-
nancies have proven to be challenging to study but cells
with stem like properties have been reported in most of
these diagnoses. As discussed below it appears that in
each case of the chemotherapy curable malignancies
they do not have standard hierarchical cancer stem cell
structure, however they do have a population of cells
that have developed cancer stem cell qualities when aris-
ing from the malignant cells themselves in a stochastic
or non-hierarchical model.
Fig. 1 The Hierarchical Cancer Stem Model. In this simplified model, the standard somatic stem cells, give rise to healthy cells and also maintain
their stem cell pool. In the epithelial cancers the somatic stem cells can give rise to the hierarchical cancer stem cells that retains much of the
properties of the somatic stem cell, but gives rise to cancer cells. In some malignancies, cells with stem-like qualities can arise from within the
tumour cell pool in a stochastic model
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The origin of the cancer stem cells in these malignan-
cies may have a dramatic impact on their characteristics.
Whilst the hierarchical stem cells will share many char-
acteristics with the tissue specific somatic stem cells
from which they arise, the stochastic stem cells arising
from within the cancer cell pool whilst taking on some
of the acquired characteristics of stemness, will also take
on some of the primary biological properties of the ma-
lignant cell [53]. We would argue that the stochastic
cancer stem cell in taking on key biological traits of the
parent cancer cell from which they arise would include
assuming the inherent apoptotic sensitivity of the malig-
nant cell linked to the unique genetic event that is asso-
ciated with each chemotherapy curable cancer type [4].
In acute lymphocytic leukemia
ALL characteristically arises in pro-B cells that have or
are undergoing VDJ recombination of their immuno-
globulin genes [26]. B cells at this point in development
have been shown to be dramatically more sensitive,
compared to myeloid cells and mature B cells, to DNA
damage from radiation or chemotherapy [54].
Research into the existence and potential characteris-
tics of cancer stem cells in acute lymphocytic leukemia
(ALL) has been an area of considerable endeavour. A
number of studies have indicated that there is no cancer
stem cell hierarchy in ALL [28, 55, 56] but that the ma-
jority of ALL cells have the potential stem cell properties
of being able to self-renew and to transplant the disease
in xenograft models [57]. As in the other B cell and T
cell malignancies, the events of VDJ recombination
breaks the link from the original chemotherapy resistant
tissue HSC. As the stochastic cancer stem cells in ALL
arise from the ALL cells themselves, we would postulate
they will have the VDJ associated apoptotic sensitivity
that is present in pro-B cells still active. This will give
the ALL cells and their stochastic stem cell their great
sensitivity to chemotherapy and results in the ability to
have routine curative chemotherapy treatment as both
cancer cells and the ALL stochastic cancer stem cells
will remain exquisitely sensitive to DNA damage in-
duced apoptosis.
In non-Hodgkin’s lymphoma and Hodgkin’s disease
Lymphoma presents a range of diagnoses of B cell malig-
nancies arising from mature B cells that have completed
VDJ recombination. Cells with stem like properties have
been identified in a number of types of mature B cell ma-
lignancies including chronic lymphocytic leukemia (CLL),
follicular lymphoma and myeloma [58–60]. In keeping
with the earlier observations, these stem cells all appear to
arise from within the pool of the relevant malignant cells
and do not have the conventional hierarchical stem cell
structure that is seen in epithelial malignancies [58].
Similarly in Hodgkin’s disease, B cells able to generate and
maintain Reed Sternberg cells have been previously identi-
fied, these cells have the stem cell marker ALDH and are
CD27 + ve but share the clonal immunoglobulin gene
recombination with the Reed Sternberg cells [61] confirm-
ing the lack of a hierarchical structure.
Other mature B cell malignancies
We have previously hypothesised that the relationship to
the onset of malignancy and the relationship with the
VDJ or SHM activity determines much of the sensitivity
of the malignant cells to chemotherapy and would argue
that this degree of sensitivity is maintained in the sto-
chastic cancer stem cells arising from these malignan-
cies. The malignancies closely linked to VDJ and SHM,
ALL, DLBCL, Hodgkin’s disease and Burkitt’s lymphoma
are routinely curable with chemotherapy. However in
contrast in malignancies arising distant from these gen-
etic events; CLL, mantle cell lymphoma and multiple
myeloma are not chemotherapy curable. We would
argue that the apoptotic sensitivity linked to VDJ and
SHM is absent in these cells distant from these events
so determining the lack of extreme chemotherapy sensi-
tivity in both the malignant cells and their counterpart
stochastic stem cells.
In gestational trophoblast tumours
The pregnancy associated malignancies of post molar
pregnancy trophoblast tumour and gestational chorio-
carcinoma are rare but highly curable with chemother-
apy treatment [62, 63]. The model of cancer stem cells is
perhaps less relevant to these cells and their malignan-
cies as they arise from the initial cells that are formed at
fertilisation and nuclear fusion. Whilst in this situation
there can be no hierarchical cancer stem cells, as these
cells arise from the first point in embryological develop-
ment, recent work has indicated the presence of cancer
cells with stem like properties developing within tropho-
blast cell lines [64]. We would suggest that the cells with
stem like properties in this malignancy will share the in-
nate sensitivity to chemotherapy that the trophoblast
cells have naturally due to their close temporal relation-
ship with the unique genetic event of nuclear fusion and
the associated apoptotic sensitivity [4].
In germ cell tumours
Germ cell tumours are rare and predominantly arise
from the pre-malignant precursors carcinoma in situ
(CIS) in men and gonadoblastoma in women [65, 66].
Both of these contain fetal gonocytes that have matured
incorrectly and have an altered balance of the meiotic/
mitotic switch [67]. The malignant cells that arise from
these cells are extremely sensitive to chemotherapy and
patients with advanced germ cell tumours are routinely
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cured. Similarly to the other chemotherapy curable ma-
lignancies these cells are biologically isolated from the
standard tissue specific stem cell, the spermatogonial
stem cell as a result of their developmental pathway.
Whilst testicular cancer cells with stem cell like proper-
ties have been described, they appear to be extremely
sensitive to chemotherapy and radiation [68]. These
cells also arise in a stochastic non-hierarchical way
from the cancer cells themselves and we would hypoth-
esis that the germ cell cancer stem cells share the can-
cer cells innate apoptotic sensitivity to chemotherapy
resultant from their developmental proximity to the
meiotic pathway [4].
In the childhood malignancies
The childhood malignancies have less clear developmen-
tal pathways but are generally believed to arise from em-
bryological cells with blocked and failed development.
We have previously postulated that the high apoptotic
potential and chemotherapy curability of these rare ma-
lignancies is linked to the development of the malignant
phenotype and blocked development occurring soon
after gastrulation [4].
In neuroblastoma the malignant cells are primitive
cells with blocked embryological development that pre-
vents normal cellular differentiation [69]. Cells with can-
cer stem properties have been identified within the
tumour cells and these cells can self renew, differentiate
to all of the constituent parts of neuroblastoma and ef-
fectively produce tumours in mice [70]. In Wilms’ tu-
mours recent studies have indicated that the cancer
stem cells are not early renal stem cells but are a more
developed cell that can serve to de-differentiate to pro-
duce the full repertoire of cells seen in the malignancy
[71]. Similarly in the other childhood chemotherapy cur-
able malignancies, Ewing’s sarcoma and osteosarcoma
the cancer stem cells that have been identified do not
follow the conventional hierarchical model with Ewing’s
potentially arising from a derivative of a mesenchymal
stem cell [72].
The finding that these other potentially chemotherapy
curable malignancies do not arise in the conventional
hierarchical manner from cancer stem cells related to
standard tissue specific stem cells, also helps explain
why these tumours frequently do not relapse after suc-
cessful chemotherapy treatment.
Each of the chemotherapy curable malignancies
lacks hierarchical cancer stem cells
In the chemotherapy curable malignancies, the cells of
each diagnosis arise from a cell which would normally
have a transient passage through a complex develop-
mental stage during which they become malignant. In
health, a normal cell does not persist long term as a new
trophoblast cell, or as a pro-B cell or germinal centre B
cell, similarly the process of meiosis occupies only a rela-
tively brief step in the complete pathway of production
of sperm from sperm stem cells. In health cells passing
through these developmental stages, do so for a rela-
tively short length of time, and then exit to either the
next stage in their development after their unique gen-
etic event successfully occurs or naturally undergo apop-
tosis in response to event related DNA damage or an
absence of positive selection.
In the common solid malignancies the hierarchical rela-
tionship of the tissue specific somatic stem cell, the cancer
stem cell and the cancer cells is relatively simple with the
tissue specific stem cell giving rise through mutation to the
cancer stem cell and the cancer stem cells in turn giving
rise to the more rapidly growing standard cancer cells [73].
In contrast in the chemotherapy curable malignancies
the relationship and role of cancer stem cells is more
complex and at present less clearly defined. The bio-
logical difference is most easily seen in the B cell and T
cell malignancies where there is a very differing relation-
ship with their stem cells than most conventional malig-
nant cells. Here the stem cell that is the original source
of cells for all lymphoid and myeloid malignancies is the
haematopoietic stem cell (HSC). However this cell,
which is very resistant to chemotherapy, only acts in the
conventional stem situation for the initial lead off into B
cell, T cell and myeloid cell development. After this
point the B cell and T cells undergo the complex genetic
recombinations of V(D)J genes and for the B cells som-
atic hypermutation and class switching that lead to their
specific clonal identity. These processes in which DNA
is cut, rearranged, mutated, rejoined and repaired con-
tain much of the risk of DNA damage that leads to leu-
kamagenesis and lymphomagenesis [74] but also provide
the pathways that allow these malignancies to be chemo-
therapy curable [3].
The malignancies that arise further along these path-
ways and more distant from the HSC are physiologically
very different cells and now clonally and mutationally
only very distantly related to the original HSC. Whilst
HSC that carry mutations have been recognised to con-
firm a risk of development of CLL, these cells are not
directly clonally related to a current diagnosis of CLL
and cannot serve to repopulate the pool of established
CLL cells after chemotherapy treatment [75]. Whilst it is
apparent that B cell and T cell malignancies cannot have
cancer stem cells in the same hierarchical way that the
common cancers may do, it is postulated that leukemia,
lymphoma and other lymphoid malignancies can contain
cells with stem like properties that are derived in a sto-
chastic method from the malignant cells that arise at the
key differing points along the B cell and T cell develop-
ment pathway [58].
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In a similar fashion there is a similar lack of conven-
tional hierarchical cancer stem cells for the other
chemotherapy curable malignancies. In the gestational
tumours the malignant cells arise from the primitive
trophoblast cells, which are present for only short time
after conception and nuclear fusion. Similarly the malig-
nant germ cell tumours have no healthy counterpart and
are believed to arise from arrested gonocytes that having
ongoing meiosis/mitosis stresses. These cells are not
present in health and the malignant germ cell tumour
cells are not supported by stem cells arising from the
spematogonial stem cells.
These biological observations suggests that the chemo-
therapy curable malignancies share a common theme in
that they do not have conventional hierarchical cancer
stem cells. In each case their cancer stem cells appear to
arise either from within the cancer cell pool in the sto-
chastic model, as in ALL, lymphoma and choriocarcin-
oma, or from a persistent embryonal cell with blocked
development as in the childhood malignancies and germ
cell tumours. In Table 1 a summary of chemotherapy
curability of the key tumour types along with their hier-
archical stem cell status and relationship to the malig-
nancy associated genetic events is demonstrated.
Chemotherapy curable and non-curable B cell malignancies
and stochastic cancer stem cells
This observational model on the relationship between
the chemotherapy curability of cancer cells and their
stem cells is complicated in that some types of B cell
and T cell malignancies including CLL, follicular NHL,
multiple myeloma and the mature T cell malignancies
also will share the same non-hierarchical stem cell
model, frequently respond well to chemotherapy treat-
ment but are not curable with chemotherapy.
In this situation we would argue that the characteris-
tics of the stochastic stem cells with regard to DNA
damage and induction of apoptosis is not determined
solely by the process of their development of stem cell
characteristics but is also very significantly affected by
the intrinsic characteristics of the malignant cell from
which they arise [53]. Figure 2 shows the potential im-
pact of this in the differing chemotherapy curability of
the B cell malignancies. The stochastic stem cells arising
from ALL will still have the apoptotic sensitivity linked
to VDJ activated, similarly the stochastic stem cells in
DLBCL will still have the SHM associated apoptotic sen-
sitivity. In contrast in the stochastic stem cells arising
from CLL, follicular lymphoma and multiple myeloma
Fig. 2 The Properties of Stochastic Stem Cells in B Cell Malignancies. In B cell malignancies the main cancer mutational events occur during
VDJ recombination and somatic hypermutation. The resultant malignant cells that arise during B cell development remain fixed at that point in
development and neither progress to be terminally differentiated plasma cell or undergo apoptotic death as B cells that fail developmental
checks normally do. Dependant on the timing of the onset of the malignant phenotype the B cell takes on the phenotype of the cell of origin.
Each of the malignant cell types are developmentally isolated from the HSC but can develop stochastic cells with stem like qualities, including a
degree of resistance to chemotherapy. We suggest that there is a balance of this stem like acquired chemotherapy resistance against the
apoptotic sensitivity linked to the upregulated activity in B cell development related to VDJ and SHM activity. This balance determines if the
differing stochastic stem cells will survive chemotherapy and hence if the B cell malignancy can have the potential to be cured with
chemotherapy or not
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cells in which these processes are not active, will not
have this overpowering apoptotic sensitivity and are able
to resist chemotherapy induced damage and can serve to
repopulate the malignancy after chemotherapy treat-
ment. We would hypothesise that the ongoing activity of
these genetic recombination related apoptotic pathways
are sufficiently active to overcome the degree of resist-
ance associated with development of stemness in the
stochastic cancer stem cell and leave these biologically
unique cancer stem cells sensitive to chemotherapy
treatment.
Conclusions
The ability of simple cytotoxic DNA damaging chemo-
therapy drugs used as single agents or more commonly
in combination to cure a select group of relatively rare
malignancies has been one of the great achievements
from the early days of cancer therapeutics in the
1950–70s. However since then, despite enormous en-
deavour, no additional metastatic malignancy has been
added to the short list of routinely curable metastatic
cancers.
This dramatic divergence in responsiveness between
different malignancies to chemotherapy treatment and
how to improve it, has been one of the major areas of
oncology research. In this paper we have reviewed how
the cancer stem cell structure associated with these ma-
lignancies may impact on this divergence.
Our observations indicate that each of the chemother-
apy curable malignancies arise in a cell type that has a
transient passage through a complex developmental
stage involving complex DNA manipulation. The con-
ventional hierarchical cancer stem cell system is absent
in each of the chemotherapy curable malignancies and
these factors are likely to be an important associations
with the dramatic and divergent responses seen to chemo-
therapy. Additionally each of the chemotherapy curable
cancers arises from a parent cell that has much lower
levels of ABC transporter protein expression than hier-
archical cancer stem cells have is also likely to lead to a
further increase in efficacy of chemotherapy treatment.
In the chemotherapy curable malignancies the cancer
stem cells where present, generally arise in a non-
hierarchical or stochastic method from within the pool
of tumour cells itself. In each malignancy these cells are
either developmentally isolated from their originating
tissue specific somatic stem cells or have no conven-
tional hierarchical cancer stem cells. As a result of the
absence of a hierarchical cancer stem cells, the chemo-
therapy curable malignancies can only have cells with
stem cell like properties that have arisen from with the
cancer cell pool. These cells will take much of their
properties from the cancer cells rather than having the
propertices of a conventional cancer stem cell that is
closely related to the damage and chemotherapy resist-
ant somatic stem cells.
We have previously postulated the potential import-
ance regarding the presence of the key cellular pro-
apoptotic sensitivity associated with the unique genetic
events of nuclear fusion, VDJ recombination, somatic
hypermutation, meiosis and gastrulation. Normal healthy
cells undergoing these activities are exceptionally sensi-
tive to the action of chemotherapy drugs, as seen in the
action of methotrexate in producing pregnancy loss [76],
of chemotherapy in removing CIS [77] and the enor-
mous sensitivity of healthy early B cells to cytotoxics
[54, 78]. The ongoing activity of the apoptotic pathways
associated with these processes in cells frozen at these
points in development could be an important determin-
ant of chemotherapy curability in the malignancies
arising in them [3, 4].
We would argue that this association also directly im-
pacts on the chemotherapy sensitivity of the non-
hierarchical or stochastic cancer stem cells associated
with these varied malignancies. In this situation the re-
sponsiveness to chemotherapy of the stochastic cancer
stem cell will be determined by both the acquired char-
acteristics of stemness but also significantly impacted by
the underlying apoptotic sensitivity of the malignant cell.
As a result, in the chemotherapy curable malignancies
the degree of chemotherapy resistance that the adoption
of stemness gives to these stochastic cancer stem cells, is
functionally outweighed by the apoptotic sensitivity and
allows the chemotherapy to kill the stem cells. In con-
trast in the similar malignancies of CLL/mantle cell
lymphoma/myeloma/low grade NHL which also have
stochastic stem cells and no hierarchical stem cells, their
stochastic stem cells do not have this extreme apoptotic
sensitivity and their stem cells are able to survive the
chemotherapy, in a similar fashion to standard hierarch-
ical cancer stem cells.
In this debate section, it is clear that there is a great
deal of data needed to confirm or repudiate this new hy-
pothesis. To date there has been only limited research
on these natural apoptotic pathways, their mechanisms
and the controls occurring in these cells. Additionally
there has been also limited work on the differential
apoptotic responses of the chemotherapy curable malig-
nancies compared with the incurable. However whilst
this paper may serve as a prompt to explore these areas
in more depth it should also serve to remind that the
genes that can give rise to overwhelming apoptosis in re-
sponse to chemotherapy are present in every cancer cell
and in their respective cancer stem cell. The key of how
to unlock this potential is awaited.
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